[The value of psychopharmacotherapy in the treatment of borderline personality disorder].
The interest in the psychopharmacological treatment of the borderline personality disorder (BPS) has been steadily increased in the last years. There isn't, however, any investigation, which has proved the existence of a specific "Anti-Borderline-Drug" yet. There are, however, identifiable drug-responsive syndromes. The description by Coccaro and Karoussi (1991) of a syndrome of affective instability (abnormalities in the brain's adrenergic and cholinergic systems, respond to carbamazepine and lithium), transient psychotic phenomena (abnormalities in the central dopaminergic systems, respond to low-dose neuroleptics) and impulsive, aggressive behaviour (abnormalities in the central serotonergic systems, respond to serotonergic agents) seems to be very promising in this regard.
Leitner
P
P
Klinikum Berlin-Buch, Psychiatrische Klinik, Berlin.
Serfling
R
R
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000523:psychology; D002220:Carbamazepine / Q000627:therapeutic use; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D005473:Fluoxetine; D001569:Benzodiazepines; D002220:Carbamazepine
Die Stellung der Psychopharmakatherapie in der Behandlung der Borderline-Persönlichkeitsstörung.